Everything below concerns dihexa. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
== Organisations == Tactical recognition flash, UK armed forces Texas Renaissance Festival, USA Thoroughbred Retirement Foundation, racehorse rescue organization TRF (group), a J-pop group Regional Federal Courts (Portuguese: Tribunais Regionais Federais), Brazilian Federal appellate courts The Resistance Front, a separatist group in Indian Kashmir
===== Cetacean research ===== Peacock & Thewissen (2026) compare volume measurements of the bony labyrinth in extant mammals and Eocene cetaceans, and hypothesize that fossil cetaceans had membranous ducts of relatively larger size compared to terrestrial even-toed ungulates, and that vestibular organs of early cetaceans were necessary for terrestrial locomotion. Buono et al. (2026) reconstruct changes of cetacean morphological diversity and ecospace occupancy throughout the evolutionary history of the group, identifying Eocene–Oligocene and Plio–Pleistocene transitions as periods of major evolutionary changes, and linking changes of ecospace occupancy to the main radiation events of the group. Tyborowski et al. (2026) report the discovery of a portion of a dentary of an indeterminate member of Pelagiceti from the Siemień Formation, representing the first record of an Eocene whale from Poland and one of the smallest fully aquatic Eocene whales reported to date. A deciduous tooth of a basilosaurid with evidence of malformation that might have been caused by localized stress is described from the Eocene Submeseta Formation (Seymour Island, Antarctica) by Bajor et al. (2026). Hakkens, Reumer & Schulp (2026) study the affinities of the basilosaurid specimen TM 8501 from the Eocene (Priabonian) Yazoo Clay (Alabama, United States; the holotype of Zeuglodon hydrarchus), identify the studied individual as a mid-sized cetacean distinct from Dorudon serratus and Chrysocetus healyorum, an tentatively refer the specimen to Zygorhiza kochii. Davydenko et al.
Nuclear warfare, also known as atomic warfare, is a military conflict or prepared political strategy that deploys nuclear weaponry. Nuclear weapons are weapons of mass destruction; in contrast to conventional warfare, nuclear warfare can produce significantly more destruction in a much shorter time and can have a long-lasting radiological result. A large nuclear exchange would kill hundreds of millions of people. It would have long-term effects, from the fallout released, and could also lead to secondary effects, such as nuclear winter, nuclear famine, and societal collapse. A global nuclear war with current national stockpiles may lead to various devastating scenarios, including human extinction. As of 2026, the first and only use of nuclear weapons in armed conflict was the United States atomic bombings of Hiroshima and Nagasaki, on August 6 and 9, 1945, in the final days of World War II. The two bombings resulted in the deaths of between 150,000 and 246,000 people. A debate continues over ethical, legal, and military aspects of the bombings, including their role in the surrender of Japan. The Cold War prompted the nuclear arms race. Nuclear weapons were later developed by the Soviet Union (1949), the United Kingdom (1952), France (1960), and China (1964). In 1974, India, and in 1998, Pakistan, with a history of conflict, developed nuclear weapons. Israel (1960s) and North Korea (2006) also developed nuclear weapons.
Hood's research group corrected the neurological defect in mice (the shiverer defect) by transferring a normal MBP gene into the fertilized egg of the shiverer mouse. These discoveries led to extensive studies of MBP and its biology.
Sources: en.wikipedia.org
Following the November 2008 terrorist attacks in Mumbai, Hitchens argued in a radio interview with Hugh Hewitt that Pakistan's Inter-Services Intelligence (ISI) bore substantial responsibility for the attacks and pressed for the United States to realign its South Asia policy away from Pakistan and more firmly toward India. He stated that Pakistan had used militant groups as proxies "to colonize Afghanistan" and to apply "strategic depth against India in Kashmir," and described Pakistan as a "rogue, failed state."
Critical Reviews in Clinical Laboratory Sciences is a peer-reviewed medical journal that publishes review articles on all aspects of clinical laboratory sciences on an invitation-only basis. The journal is published by Taylor and Francis and the editor-in-chief is Khosrow Adeli (University of Toronto). According to the Journal Citation Reports, the journal has a 2019 impact factor of 4.677.
when it maintains a charge q and travels through an electric field E and magnetic field B with a velocity v. The secondary ions that leave the surface of the sample typically have a kinetic energy of a few electron volts (eV), although a rather small portion have been found to have energy of a few keV. An electrostatic field captures the secondary ions that leave the sample surface; these extracted ions are then transferred to a mass spectrometer. In order to achieve precise isotope measurements, there is a need for high transmission and high mass resolution. High transmission refers to the low loss of secondary ions between the sample surface and the detector, and high mass resolution refers to the ability to efficiently separate the secondary ions (or molecules of interest) from other ions and/or ions of similar mass. Primary ions will collide with the surface at a specific frequency per unit of surface area. The collision that occurs causes atoms to sputter from the sample surface, and of these atoms only a small amount will undergo ionization. These become secondary ions, which are then detected after transfer through the mass spectrometer. Each primary ion generates a number of secondary ions of an isotope that will reach the detector to be counted. The count rate is determined by
== History == Famotidine was developed by Yamanouchi Pharmaceutical Co. It was licensed in the mid-1980s by Merck & Co. and is marketed by a joint venture between Merck and Johnson & Johnson. The imidazole ring of cimetidine was replaced with a 2-guanidinothiazole ring. Famotidine proved to be nine times more potent than ranitidine, and thirty-two times more potent than cimetidine. It was first marketed in 1981. Pepcid RPD orally disintegrating tablets were released in 1999. Generic preparations became available in 2001, e.g. Fluxid (Schwarz) or Quamatel (Gedeon Richter Ltd.). In the United States and Canada, a product called Pepcid Complete, which combines famotidine with an antacid in a chewable tablet to relieve the symptoms of excess stomach acid quickly, is available. In the UK, this product was known as PepcidTwo until its discontinuation in April 2015. Famotidine has poor bioavailibility (50%) due to its low solubility in the high pH of the intestines. Researchers are developing formulations that use gastroretentive drug delivery systems such as floating tablets to increase bioavailability by promoting local delivery (directly into the stomach wall) of these drugs to receptors in the parietal cell membrane.
=== May === 1 May: 5,000 senior doctors affiliated with the Association of Salaried Medical Specialists strike in response to a pay dispute with national health service Health New Zealand. States of emergency are declared in Selwyn District, Christchurch and Banks Peninsula due to flooding and landslides, amid poor weather affecting most of the country. About a thousand properties in Wellington experience power outages. Most flights to and from the city are cancelled, and so are Cook Strait ferry crossings. Wind gusts in the city reach up to 150 km/h. 2 May – The state of emergency is lifted in the Selwyn District. States of emergency remain in effect in Christchurch and Banks Peninsula. 3 May – 400 protesters gather in Dunedin's Octagon to protest against the New Zealand First party's member's bill defining women and men based on their sexual biology. 6 May – The Commerce Commission files criminal charges against supermarket giant Woolworths for alleged inaccurate pricing and misleading discounts. 7 May: Convicted murderer Mark Lundy is released on parole after serving 23 years of a life sentence for the murders of his wife Christine and daughter Amber in August 2000. The New Zealand Government ends the requirement for overseas visitors to provide certified translations of supporting documents in a bid to boost tourism. The New Zealand Parliament passes urgent legislation raising the threshold for making pay equity claims. As a result, 33 claims representing thousands of workers have to be dropped and refiled.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.